伊他替尼预防单倍体移植中移植物抗宿主病与细胞因子释放综合征
本研究为开放标签单臂研究,42例接受单倍体造血细胞移植的患者在标准GVHD预防基础上加用伊他替尼200 mg每日一次,从-3天至+100或+180天后逐渐减量。结果显示无2-5级CRS,+180天内无3-4级急性GVHD,1年OS为80%,非复发死亡累积发生率为8%。
要点
- 伊他替尼联合标准GVHD预防在单倍体移植中耐受良好。
- 所有患者CRS为0级(22%)或1级(78%),无2-5级CRS。
- +100天2级aGVHD累积发生率为21.9%,1年中重度cGVHD为5%。
核心结论
- 伊他替尼加入标准GVHD预防后耐受良好,CRS、急慢性GVHD及NRM发生率低,无GVHD无复发生存和OS率令人鼓舞。
研究设计与样本
- 开放标签、单臂研究,评估伊他替尼联合标准GVHD预防在单倍体造血细胞移植后的安全性和有效性。
- 共42例患者接受伊他替尼200 mg每日一次,从-3天至+100或+180天,随后逐渐减量。
主要发现
- 所有患者CRS为0级(22%)或1级(78%),无2-5级CRS病例。
- 无原发植入失败病例。
- +180天内无患者发生3-4级急性GVHD。
- +100天2级aGVHD累积发生率为21.9%。
- 1年中度或重度慢性GVHD累积发生率为5%。
关键数值与推荐
- 2年复发累积发生率为14%。
- 1年OS为80%。
- +180天NRM累积发生率为8%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haploidentical hematopoietic cell transplantation (haplo-HCT) is an increasingly used treatment for hematologic malignancies. Although posttransplant cyclophosphamide (PtCy) has improved graft-versus-host disease (GVHD) prophylaxis in haplo-HCT, patients continue to experience life-threatening complications. Interferon gamma and interleukin-6 are central in the pathophysiology of GVHD and cytokine release syndrome (CRS), and both cytokines signal through Janus kinase 1 (JAK-1). We tested the effect of adding the JAK-1 selective inhibitor, itacitinib, to PtCy-haplo-HCT to mitigate these complications and improve overall survival (OS). This open-label, single-arm study evaluated the safety and efficacy of itacitinib combined with standard GVHD prophylaxis after haplo-HCT. A total of 42 patients were treated with itacitinib 200 mg daily from day -3 through +100 or +180, followed by a taper. Itacitinib resulted in low CRS grades, all patients had grade 0 (22%) or grade 1 (78%) CRS and there were no cases of grade 2 to 5 CRS. There were no cases of primary graft failure. No patients developed grade 3 to 4 acute GVHD (aGVHD) through day +180. The cumulative incidence of grade 2 aGVHD at day +100 was 21.9%. The 1-year cumulative incidence of moderate or severe chronic GVHD was 5%. The cumulative incidence of relapse at 2 years was 14%. OS at 1 year was 80%. The cumulative incidence of nonrelapse mortality (NRM) at day 180 was 8%. Itacitinib, when added to standard GVHD prophylaxis, was well tolerated and resulted in low rates of CRS, acute and chronic GVHD, and NRM, and encouraging rates of GVHD-free relapse-free survival and OS after haplo-HCT. This trial was registered at www.ClinicalTrials.gov as #NCT03755414.
引用
- Abboud R, Schroeder MA, Rettig MP, et al. Itacitinib for prevention of graft-versus-host disease and cytokine release syndrome in haploidentical transplantation. Blood. 2025. PMID: 39576962. doi:10.1182/blood.2024026497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。